2.18
-0.04(-1.80%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.24 |
| Day High | 2.24 |
| Day Low | 2.12 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 69,222 |
| Average Volume | 1.43M |
| Market Cap | 22.7M |
| PE | -0.55 |
| EPS | -3.99 |
| Moving Average 50 Days | 2.15 |
| Moving Average 200 Days | 2.38 |
| Change | -0.04 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $21.48 as of August 18, 2025 at a share price of $2.18. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $192.92 as of August 18, 2025 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved ali
SAB BIO Announces Oversubscribed $175 Million Private Placement
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
GlobeNewswire Inc.
May 09, 2025 1:00 PM GMT
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying